205 related articles for article (PubMed ID: 29500147)
21. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
22. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
Sermer D; Bobillo S; Dogan A; Zhang Y; Seshan V; Lavery JA; Batlevi C; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Palomba ML; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A
Blood Adv; 2020 Jul; 4(14):3382-3390. PubMed ID: 32722781
[TBL] [Abstract][Full Text] [Related]
23. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
24. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
25. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
26. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
Chihara D; Westin JR; Oki Y; Ahmed MA; Do B; Fayad LE; Hagemeister FB; Romaguera JE; Fanale MA; Lee HJ; Turturro F; Samaniego F; Neelapu SS; Rodriguez MA; Fowler NH; Wang M; Davis RE; Nastoupil LJ
Cancer; 2016 Oct; 122(20):3145-3151. PubMed ID: 27351173
[TBL] [Abstract][Full Text] [Related]
27. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
28. Double-Hit and Triple-Hit Follicular Lymphoma.
Ziemba JB; Wolf Z; Weinstock M; Asakrah S
Am J Clin Pathol; 2020 Apr; 153(5):672-685. PubMed ID: 32112707
[TBL] [Abstract][Full Text] [Related]
29. Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Oki Y; Noorani M; Lin P; Davis RE; Neelapu SS; Ma L; Ahmed M; Rodriguez MA; Hagemeister FB; Fowler N; Wang M; Fanale MA; Nastoupil L; Samaniego F; Lee HJ; Dabaja BS; Pinnix CC; Medeiros LJ; Nieto Y; Khouri I; Kwak LW; Turturro F; Romaguera JE; Fayad LE; Westin JR
Br J Haematol; 2014 Sep; 166(6):891-901. PubMed ID: 24943107
[TBL] [Abstract][Full Text] [Related]
30. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
31. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
32. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
33. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Zayac AS; Landsburg DJ; Hughes ME; Bock AM; Nowakowski GS; Ayers EC; Girton M; Hu M; Beckman AK; Li S; Medeiros LJ; Chang JE; Stepanovic A; Kurt H; Sandoval-Sus J; Ansari-Lari MA; Kothari SK; Kress A; Xu ML; Torka P; Sundaram S; Smith SD; Naresh KN; Karimi YH; Epperla N; Bond DA; Farooq U; Saad M; Evens AM; Pandya K; Naik SG; Kamdar M; Haverkos B; Karmali R; Oh TS; Vose JM; Nutsch H; Rubinstein PG; Chaudhry A; Olszewski AJ
Blood Adv; 2023 Nov; 7(21):6381-6394. PubMed ID: 37171397
[TBL] [Abstract][Full Text] [Related]
34. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
Barraclough A; Alzahrani M; Ettrup MS; Bishton M; van Vliet C; Farinha P; Gould C; Birch S; Sehn LH; Sovani V; Ward MS; Augustson B; Biccler J; Connors JM; Scott DW; Gandhi MK; Savage KJ; El-Galaly T; Villa D; Cheah CY
Blood Adv; 2019 Jul; 3(13):2013-2021. PubMed ID: 31285189
[TBL] [Abstract][Full Text] [Related]
35. Double-Hit Large B Cell Lymphoma.
Khelfa Y; Lebowicz Y; Jamil MO
Curr Oncol Rep; 2017 Sep; 19(11):74. PubMed ID: 28952038
[TBL] [Abstract][Full Text] [Related]
36. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
37. Emerging Strategies in Treating Double Hit Lymphomas.
Nabhan C; Mato AR
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):563-568. PubMed ID: 28711572
[TBL] [Abstract][Full Text] [Related]
38. Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A; Stevenson P; Cassaday RD; Soma L; Fromm JR; Gopal AK; Smith SD; Till B; Lynch RC; Ujjani C; Shadman M; Warren EH; Menon M; Russell K; Tseng YD
Pract Radiat Oncol; 2020; 10(1):44-52. PubMed ID: 31585205
[TBL] [Abstract][Full Text] [Related]
39. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
[TBL] [Abstract][Full Text] [Related]
40. Dose-adjusted EPOCH-R is a safe and well tolerated outpatient treatment regimen in double-hit lymphoma.
Nelles R; Morris K; Scott A; Kennedy G
Intern Med J; 2023 May; 53(5):773-778. PubMed ID: 35289474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]